Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Mai H. Le"'
Autor:
Robert Wesolowski, Neelesh Sharma, Laura Reebel, Mary Beth Rodal, Alexandra Peck, Brian L. West, Adhirai Marimuthu, Paul Severson, David A. Karlin, Afshin Dowlati, Mai H. Le, Lisa M. Coussens, Hope S. Rugo
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 11 (2019)
Purpose: To evaluate the safety, recommended phase II dose (RP2D) and efficacy of pexidartinib, a colony stimulating factor receptor 1 (CSF-1R) inhibitor, in combination with weekly paclitaxel in patients with advanced solid tumors. Patients and Meth
Externí odkaz:
https://doaj.org/article/26e5bc3db4084f12bdaf56d54e8bff23
Autor:
Lawrence Fong, Adil I. Daud, Mai H. Le, Robert H. Pierce, Alan Paciorek, Li Zhang, Christopher G. Twitty, Lawrence Chen, Kathryn T. Takamura, Katy K. Tsai, Alain P. Algazi, Samantha K. Greaney
Whereas systemic IL12 is associated with potentially life-threatening toxicity, intratumoral delivery of IL12 through tavokinogene telseplasmid electroporation (tavo) is safe and can induce tumor regression at distant sites. The mechanism by which th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28ba2b2721404c2e21aea696350dbd37
https://doi.org/10.1158/2326-6066.c.6550222.v1
https://doi.org/10.1158/2326-6066.c.6550222.v1
Autor:
Lawrence Fong, Adil I. Daud, Mai H. Le, Robert H. Pierce, Alan Paciorek, Li Zhang, Christopher G. Twitty, Lawrence Chen, Kathryn T. Takamura, Katy K. Tsai, Alain P. Algazi, Samantha K. Greaney
Supplementary Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8dd29f92e0542fe150bc20a0a767f4d2
https://doi.org/10.1158/2326-6066.22543339.v1
https://doi.org/10.1158/2326-6066.22543339.v1
Autor:
Lawrence Fong, Adil I. Daud, Mai H. Le, Robert H. Pierce, Alan Paciorek, Li Zhang, Christopher G. Twitty, Lawrence Chen, Kathryn T. Takamura, Katy K. Tsai, Alain P. Algazi, Samantha K. Greaney
Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28a38f95a7d47fb4f42ac46e7f9e5046
https://doi.org/10.1158/2326-6066.22543342.v1
https://doi.org/10.1158/2326-6066.22543342.v1
Autor:
Neil P. Shah, Gideon Bollag, Brian L. West, Gaston Habets, Henry H. Hsu, Mai H. Le, Prabha N. Ibrahim, Wayne Spevak, Jiazhong Zhang, Bernice Matusow, Elizabeth A. Burton, Ben Powell, Heidi Carias, Garson Tsang, Rafe Shellooe, Andrew Kasarskis, Alexander Perl, Robert Sebra, Ali Bashir, Matthew Pendleton, Lauren E. Damon, Evan Massi, Ying Zhang, Elisabeth A. Lasater, Kimberly C. Lin, Chao Zhang, Catherine C. Smith
Supplementary Table 1. Crystallographic Data and Refinement statistics. Supplementary Table 2. Comparing Target Inhibition by Quizartinib and PLX3397 in Engineered Ba/F3 cells Expressing FLT3-ITD, FLT3-ITD/F691L and FLT3-ITD/D835Y. Supplementary Tabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7f3238bc9253c505ce861afdefa65ccf
https://doi.org/10.1158/2159-8290.22531562.v1
https://doi.org/10.1158/2159-8290.22531562.v1
Autor:
Neil P. Shah, Ross L. Levine, Barry S. Taylor, Gideon Bollag, Brian West, Mai H. Le, Henry H. Hsu, Theodore C. Tarver, Elli Papaemmanuil, Juan S. Medina-Martinez, Matthieu Najm, Franck Rapaport, Nicholas D. Socci, Cyriac Kandoth, Evan Massi, Aaron D. Viny, Catherine C. Smith
Purpose:Biomarkers of response and resistance to FLT3 tyrosine kinase inhibitors (TKI) are still emerging, and optimal clinical combinations remain unclear. The purpose of this study is to identify co-occurring mutations that influence clinical respo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89d67214d6a1910af12b296f5a771aeb
https://doi.org/10.1158/1078-0432.c.6530567
https://doi.org/10.1158/1078-0432.c.6530567
Autor:
Neil P. Shah, Ross L. Levine, Barry S. Taylor, Gideon Bollag, Brian West, Mai H. Le, Henry H. Hsu, Theodore C. Tarver, Elli Papaemmanuil, Juan S. Medina-Martinez, Matthieu Najm, Franck Rapaport, Nicholas D. Socci, Cyriac Kandoth, Evan Massi, Aaron D. Viny, Catherine C. Smith
Supplemental Figures
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::160fb9940590a640a855d9865032f993
https://doi.org/10.1158/1078-0432.22480967.v1
https://doi.org/10.1158/1078-0432.22480967.v1
Autor:
Paul Nghiem, Adil I. Daud, Richard Heller, Robert H. Pierce, Sharron Gargosky, Mai H. Le, Jean S. Campbell, Christopher G. Twitty, Upendra Parvathaneni, David R. Byrd, Astrid Blom, Dafina Ibrani, Jayasri G. Iyer, Rima Kulikauskas, Natalie J. Miller, Natalie V. Longino, Shailender Bhatia
Figure S1, Table S1, Table S2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d9b89502ad3bb28bd2ecd97aed8b58f1
https://doi.org/10.1158/1078-0432.22473930
https://doi.org/10.1158/1078-0432.22473930
Autor:
Elli Papaemmanuil, Mai H. Le, Catherine C. Smith, Nicholas D. Socci, Brian L. West, Franck Rapaport, Ross L. Levine, Matthieu Najm, Evan Massi, Juan S. Medina-Martinez, Neil P. Shah, Henry H. Hsu, Theodore C. Tarver, Aaron D. Viny, Gideon Bollag, Barry S. Taylor, Cyriac Kandoth
Publikováno v:
Clin Cancer Res
Purpose: Biomarkers of response and resistance to FLT3 tyrosine kinase inhibitors (TKI) are still emerging, and optimal clinical combinations remain unclear. The purpose of this study is to identify co-occurring mutations that influence clinical resp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::620058d0e17b7dcd21fd8f9194430702
https://doi.org/10.1158/1078-0432.ccr-20-3458
https://doi.org/10.1158/1078-0432.ccr-20-3458
Autor:
Adil Daud, Jayasri G. Iyer, Jean S. Campbell, Robert H. Pierce, David R. Byrd, Sharron Gargosky, Dafina Ibrani, Natalie V. Longino, Natalie J. Miller, Shailender Bhatia, Christopher G. Twitty, Mai H. Le, Astrid Blom, Richard Heller, Upendra Parvathaneni, Rima M. Kulikauskas, Paul Nghiem
Publikováno v:
Clin Cancer Res
Purpose: IL12 promotes adaptive type I immunity and has demonstrated antitumor efficacy, but systemic administration leads to severe adverse events (AE), including death. This pilot trial investigated safety, efficacy, and immunologic activity of int
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25a7932c21438266e65fa0e39d4eab56
https://doi.org/10.1158/1078-0432.ccr-19-0972
https://doi.org/10.1158/1078-0432.ccr-19-0972